High‐dose intravenous immunoglobulin for post‐transfusion purpura

Becker, T; Panzer, Simon; Maas, D.; Kiefel, V.; Sprenger, R.; Kirschbaum, Michael; Mueller‐Eckhardt, C.

doi:10.1111/j.1365-2141.1985.tb04071.x

Cited by 55 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent case reports have shown the value of high-dose intravenous IgG in producing a prompt platelet response in PTP [26,33,34]. In the present case, bleeding stopped and there was a gradual increase in the platelet count after intravenous IgG, reaching normal levels after 7 days.…”

Section: Red Cell Antibodiessupporting

confidence: 48%

Post-Transfusion Purpura Associated with Anti-Bak^a and Anti-Pl^A2 Platelet Antibodies and Delayed Haemolytic Transfusion Reaction

Metcalfe¹,

Amess²,

Waters³

et al. 1987

Vox Sanguinis

View full text Add to dashboard Cite

The occurrence of post-transfusion purpura (PTP) in a 16-year-old girl with sickle/ß-thalassaemia is described. Clinically this was a typical case of PTP, but it was unusual serologically. Anti-Bak^a and anti-Pl^A2 platelet-specific antibodies were identified and the patient’s platelets were typed as homozygous Pl^A1 -positive and Bak^a-negative. The patient also developed red-cell, granulocyte and lymphocytotoxic antibodies in response to the blood transfusion and had a delayed haemolytic transfusion reaction.

show abstract

Section: Red Cell Antibodiessupporting

confidence: 48%

Post-Transfusion Purpura Associated with Anti-Bak^a and Anti-Pl^A2 Platelet Antibodies and Delayed Haemolytic Transfusion Reaction

Metcalfe¹,

Amess²,

Waters³

et al. 1987

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…The best therapy for PTP, prompting recovery of the platelet count within several days, is IVIg [21][22][23][24]26,27]. Plasmapheresis is also effective [16,[28][29][30][31][32][33][34][35].…”

Section: Discussionmentioning

confidence: 99%

“…Case reports suggest that therapy with plasmapheresis and IVIg shorten the duration of thrombocytopenia [13,[21][22][23][24][25][26][27]. IVIg is considered first-line therapy, with one or two doses (0.4 mg/kg) resulting in improved platelet counts within a few days [21,23,24,26]. Plasmapheresis is an important component of therapy Contract grant sponsor: NIH/NCI; Contract grant number: T32-CA-009679; Contract grant sponsor: NIH/NHLBI; Contract grant number: HL-54500 [16,[28][29][30][31][32][33][34][35], but it may be second to IVIg because of its relative unavailability and the risk of necessitating an invasive procedure [34].…”

Section: Introductionmentioning

confidence: 99%

“…In one series, five of 71 patients died of intracranial hemorrhage [13]; melena and hematuria were also common. Case reports suggest that therapy with plasmapheresis and IVIg shorten the duration of thrombocytopenia [13,[21][22][23][24][25][26][27]. IVIg is considered first-line therapy, with one or two doses (0.4 mg/kg) resulting in improved platelet counts within a few days [21,23,24,26].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of HPA‐1a (Pl^A1)‐negative platelets in a patient with post‐transfusion purpura

Loren

Abrams

2004

American J Hematol

View full text Add to dashboard Cite

Post-transfusion purpura (PTP) is a rare form of alloimmune thrombocytopenia that is selflimited but which carries a 10-15% mortality related to fatal hemorrhage. Immunomodulatory therapies such as plasmapheresis and intravenous immunoglobulin G (IVIg) can shorten the duration of thrombocytopenia. However, in a bleeding patient with PTP, more urgent therapy may be required. Textbooks of hematology [1][2][3] as well as reports in the literature [4,5] suggest that patients do not respond to platelet transfusions. We report a case of PTP in a patient homozygous for HPA-1b who suffered an intracranial hemorrhage. The patient was treated with IVIg and plasmapheresis. Because of her life-threatening bleeding, we also transfused the patient with HPA-1a-negative platelets. These transfusions consistently resulted in transient improvements in her platelet counts and may have limited the degree of intracranial bleeding. Our experience suggests that transfusion of platelets that lack the offending epitope in patients with PTP may be efficacious. Am.

show abstract

“…It has been postulated that the more long term effect is due to reduction in platelets antibody production [12]. In PTP, the majority of cases respond rapidly to IVIG [13]. The exact The patient, a 48-year-old multiparous woman was admitted with fresh rectal bleeding and a widespread purpuric rash.…”

mentioning

confidence: 99%

The Therapeutic Value of HPA-1a-Negative Platelet Transfusion in Post-Transfusion Purpura Complicated by Life-Threatening Haemorrhage

Win¹,

Peterkin²,

Watson³

1995

Vox Sanguinis

View full text Add to dashboard Cite

Post-transfusion purpura (PTP) was diagnosed in a female patient 1 week after transfusion for hysterectomy. Despite treatment with oral steroids and intravenous immunoglobulin, platelet counts remained low, and the patient developed profuse rectal bleeding. Random platelet transfusion is reported to be ineffective in PTP. We report a case in which the transfusion of HPA-1a negative platelets provided good increment and clinical haemostasis before intravenous immunoglobulin could have had an effect.

show abstract

High‐dose intravenous immunoglobulin for post‐transfusion purpura

Cited by 55 publications

References 18 publications

Post-Transfusion Purpura Associated with Anti-Bak^a and Anti-Pl^A2 Platelet Antibodies and Delayed Haemolytic Transfusion Reaction

Post-Transfusion Purpura Associated with Anti-Bak^a and Anti-Pl^A2 Platelet Antibodies and Delayed Haemolytic Transfusion Reaction

Efficacy of HPA‐1a (Pl^A1)‐negative platelets in a patient with post‐transfusion purpura

The Therapeutic Value of HPA-1a-Negative Platelet Transfusion in Post-Transfusion Purpura Complicated by Life-Threatening Haemorrhage

Contact Info

Product

Resources

About

High‐dose intravenous immunoglobulin for post‐transfusion purpura

Cited by 55 publications

References 18 publications

Post-Transfusion Purpura Associated with Anti-Bak^a and Anti-Pl^A2 Platelet Antibodies and Delayed Haemolytic Transfusion Reaction

Post-Transfusion Purpura Associated with Anti-Bak^a and Anti-Pl^A2 Platelet Antibodies and Delayed Haemolytic Transfusion Reaction

Efficacy of HPA‐1a (PlA1)‐negative platelets in a patient with post‐transfusion purpura

The Therapeutic Value of HPA-1a-Negative Platelet Transfusion in Post-Transfusion Purpura Complicated by Life-Threatening Haemorrhage

Contact Info

Product

Resources

About

Efficacy of HPA‐1a (Pl^A1)‐negative platelets in a patient with post‐transfusion purpura